Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with
lenvatinib in patients with advanced endometrial cancer. The primary objective is to evaluate
objective response rate of cadonilimab plus lenvatinib.